Role of β-Cell Prohormone Convertase (PC)1/3 in Processing of Pro-Islet Amyloid Polypeptide

Diabetes

Volumn 53, Issue 1, 2004, Pages 141-148

  Marzban, Lucy ^a   Trigo Gonzalez, Genny ^a   Zhu, Xiaorong ^b   Rhodes, Christopher J ^c   Halban, Philippe A ^d   Steiner, Donald F ^b   Verchere, C Bruce ^a,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^e CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; FURIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL ISOLATION; CONTROLLED STUDY; ENZYME DEFICIENCY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; WESTERN BLOTTING;

AMYLOID; ANIMALS; ISLETS OF LANGERHANS; MICE; MICE, KNOCKOUT; PROPROTEIN CONVERTASE 1; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 0346099381     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.1.141     Document Type: Article

References (38)

1. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253, 1999
2. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 46:3-19, 2003
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
4. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84:3881-3885, 1987
5. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628-8632, 1987
6. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr: Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39:634-638, 1990
7. Hoppener JW, Ahren B, Lips CJ: Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343:411-419, 2000
8. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature 368:756-760, 1994
9. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
10. Verchere CB, D'Alessio DA, Wang S, Andrikopoulos S, Kahn SE: Transgenic overproduction of islet amyloid polypeptide (amylin) is not sufficient for islet amyloid formation. Horm Metab Res 29:311-316, 1997
11. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698-702, 1987
12. Kahn SE, Halban PA: Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725-1732, 1997
13. Marzban L, Park K, Verchere CB: Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 38:347-351, 2003
14. Porte D Jr, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet beta-cell dysfunction? Diabetes 38:1333-1336, 1989
15. Hou X, Ling Z, Quartier E, Foriers A, Schuit F, Pipeleers D, Van Schravendijk C: Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors. Diabetologia 42:188-194, 1999
16. Westermark P, Engstrom U, Westermark GT, Johnson KH, Permerth J, Betsholtz C: Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract 7:219-226, 1989
17. Park K, Verchere CB: Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide: implications for islet amyloid formation. J Biol Chem 276:16611-16616, 2001
18. Kaufmann JE, Irminger JC, Mungall J, Halban PA: Proinsulin conversion in GH3 cells after coexpression of human proinsulin with the endoproteases PC2 and/or PC3. Diabetes 46:978-982, 1997
19. Fricker LD: Carboxypeptidase E. Annu Rev Physiol 50:309-321, 1988
20. Furuta M, Yano H, Zhou A, Rouille Y, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, Steiner DF: Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A 94:6646-6651, 1997
21. Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, Steiner DF: Severe block in processing of proinsulin to insulin accompanied by elevation of des-64, 65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A 99:10299-10304, 2002
22. Marcinkiewicz M, Ramla D, Seidah NG, Chretien M: Developmental expression of the prohormone convertases PC1 and PC2 in mouse pancreatic islets. Endocrinology 135:1651-1660, 1994
23. Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF: An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem 263:17243-17246, 1988
24. 2-terminal cleavage site. Diabetes 50:534-539, 2001
25. Zhu X, Zhou A, Dey A, Norrbom C, Carroll R, Zhang C, Laurent V, Lindberg I, Ugleholdt R, Holst JJ, Steiner DF: Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 99:10293-10298, 2002
26. Alarcon C, Lincoln B, Rhodes CJ: The biosynthesis of the subtilisin-related proprotein convertase PC3, but not that of the PC2 convertase, is regulated by glucose in parallel to proinsulin biosynthesis in rat pancreatic islets. J Biol Chem 268:4276-4280, 1993
27. Irminger JC, Meyer K, Halban P: Proinsulin processing in the rat insulinoma cell line INS after overexpression of the endoproteases PC2 or PC3 by recombinant adenovirus. Biochem J 320:11-15, 1996
28. Schagger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166:368-379, 1987
29. Furuta M, Carroll R, Martin S, Swift HH, Ravazzola M, Orci L, Steiner DF: Incomplete processing of proinsulin to insulin accompanied by elevation of des-31, 32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem 273:3431-3437, 1998
30. Higham CE, Hull RL, Lawrie L, Sherman KI, Morris JF, Birch NP, Docherty K, Clark A: Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267:4998-5004, 2000
31. Badman MK, Shennan KI, Jermany JL, Docherty K, Clark A: Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 378:227-231, 1996
32. Rhodes CJ, Lincoln B, Shoelson SE: Preferential cleavage of des-31, 32-proinsulin over intact proinsulin by the insulin secretory granule type II endopeptidase: implication of a favored route for prohormone processing. J Biol Chem 267:22719-22727, 1992
33. Rhodes CJ, Alarcon C: What beta-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 43:511-517, 1994
34. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, O'Rahilly S: Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16:303-306, 1997
35. O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, Gibson S, Taylor K, Carr C: Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 333:1386-1390, 1995
36. Porte D Jr: Banting Lecture 1990: beta-cells in type II diabetes mellitus. Diabetes 40:166-180, 1991
37. Roberts AN, Leighton B, Todd JA, Cockburn D, Schofield PN, Sutton R, Holt S, Boyd Y, Day AJ, Foot EA, et al.: Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci U S A 86:9662-9666, 1989
38. Bradbury AF, Smyth DG: Peptide amidation. Trends Biochem Sci 16:112-115, 1991